title: Photodynamic therapy relieves colitis and prevents colitis-associated carcinogenesis in mice.
abstract: BACKGROUND
  Inflammatory bowel diseases are incurable illnesses of the gastrointestinal tract, which substantially enhance the risk of developing colorectal carcinogenesis. Conventional photodynamic therapy is a clinically approved therapeutic modality used in the treatment of neoplastic diseases. Recent preclinical and clinical studies have shown that photodynamic therapy with low doses of photosensitizer and/or light improves inflammatory conditions, including colitis. This study aims therefore at investigating the therapeutic potential of low-dose photodynamic therapy (LDPDT) with a liposomal formulation of meta-tetra(hydroxyphenyl)chlorin (namely Foslip) in the prevention of colitis-associated cancer in mice.
  
  
  METHODS
  LDPDT efficacy was evaluated by endoscopic, macroscopic, and histological analysis. Myeloperoxidase levels were quantified by enzyme linked immunosorbent assay and cytokines expression by quantitative RT-PCR analysis. The integrity of the intestinal barrier was evaluated by immunostaining, and bacterial composition of the fecal microbiota was determined by 454 pyrosequencing of V3-V4 region of bacterial 16S rRNA genes.
  
  
  RESULTS
  LDPDT reduced intestinal tumor growth by decreasing the expression of a wide range of inflammatory mediators and by lowering neutrophil influx. LDPDT treatment prevents onset of a dysbiotic microbiota in the colitis-associated cancer model.
  
  
  CONCLUSIONS
  LDPDT with Foslip could be considered as a novel treatment modality to prevent colorectal carcinogenesis in patients with inflammatory bowel disease.
authors: *Université de Lorraine, Centre de recherche en automatique de Nancy, Vandoeuvre-lès-Nancy, France; †Centre national de la recherche scientifique, Centre de recherche en automatique de Nancy, UMR7039, Vandœuvre-lès-Nancy, France; ‡Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; §Institut National de la Santé et de la Recherche Médicale, U954, Vandoeuvre-lès-Nancy, France; ‖Gènes Diffusion, Douai, France; ¶Pegase-Biosciences, Institut Pasteur de Lille, Lille, France; and **Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, UMR1019, Lille, France.
authors: Aurélie
authors: A
authors: Reinhard
authors: Aude
authors: A
authors: Bressenot
authors: Romain
authors: R
authors: Dassonneville
authors: Alexandre
authors: A
authors: Loywick
authors: David
authors: D
authors: Hot
authors: Christophe
authors: C
authors: Audebert
authors: Sophie
authors: S
authors: Marchal
authors: François
authors: F
authors: Guillemin
authors: Mathias
authors: M
authors: Chamaillard
authors: Laurent
authors: L
authors: Peyrin-Biroulet
authors: Lina
authors: L
authors: Bezdetnaya
mesh_terms: D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000150:complications* / Q000473:pathology; D003110:Colonic Neoplasms / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D003113:Colonoscopy; D016207:Cytokines / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007124:Immunoenzyme Techniques; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008652:Mesoporphyrins / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D008652:Mesoporphyrins; D017319:Photosensitizing Agents; C072269:temoporfin